Quick Links

The MIGHT Trial

The MIGHT Trial

The main purpose of this study/trial is to test whether patients with HMGCR myopathy can be safely and effectively treated with IVIG as their only medication for this condition.

Participant Eligibility

Potential subjects must meet the following:

– Have a positive Anti-HMGCR antibody lab result within 12 months prior to enrollment

-Age 18 and older

-Demonstrate proximal muscle weakness

-Serum creatinine kinase (CK) more than 5 times the upper limit of normal


Leslie Lazar Thorn
(206) 744-9143

Additional Study Details

Full Study Title
Monotherapy IVIG for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment

Study ID: Study00009143
Start Date: 10/01/2020
End Date: 10/01/2023

James Andrews, MD

Accepts Healthy Volunteers?

Study Site(s)

University of Washington (Montlake)

1959 NE Pacific St
Seattle, Washington 98195


Use the link below to send a message to the study coordinator, or call the number above to speak directly with a study representative.

I am interested in this research study.